

1 Routine deworming during antenatal care decreases risk of neonatal 2 mortality and low birthweight: a retrospective cohort of survey data

3 Authors

4 Bhavneet Walia¹, Brittany L. Kmush¹, Sandra D. Lane¹, Timothy Endy², Antonio Montresor³, David A.
5 Larsen^{1*}

6

7 1. Syracuse University Department of Public Health, Syracuse, NY, USA

8 2. State University of New York Upstate Medical University Department of Infectious Disease,
9 Syracuse, NY, USA

10 3. Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva,
11 Switzerland

12 * Corresponding author. dalarsen@syr.edu

13 Abstract

14 Background

15 Soil transmitted helminths (STH) are a common infection among pregnant women in areas with poor
16 access to sanitation. Deworming medications are cheap and safe; however, the health benefit of
17 deworming during pregnancy is not clear.

18 Methods / Principal Findings

19 We created a retrospective cohort of more than 800,000 births from 95 Demographic and Health
20 Survey datasets to estimate the impact of deworming medicine during routine antenatal care (ANC) on
21 neonatal mortality and low birthweight. We first matched births on the probability of receiving
22 deworming during ANC. We then modeled the birth outcomes with the matched group as a random
23 intercept to estimate the effect of deworming during antenatal care after accounting for various risk
24 factors. We also tested for effect modification of soil transmitted helminth prevalence on the impact of
25 deworming during ANC. Receipt of deworming medication during ANC was associated with a 15%
26 reduction in the risk of neonatal mortality (95% confidence interval = 11-18%, n = 797,772 births), with
27 no difference between high and low transmission countries. In low transmission countries, we found an
28 11% reduction in the odds of low birth weight (95% confidence interval = 8-13%) for women receiving
29 deworming medicine and in high transmission we found a 3% reduction in the odds of low birthweight
30 (95% confidence interval = 1-5%).

31 Conclusions / Significance

32 These results suggest a substantial health benefit for deworming during ANC that may be even greater
33 in countries with low STH transmission.

34 Introduction

35 Background/rationale

36 Soil transmitted helminths (STH) are parasitic nematodes (worms) that are transmitted by
37 contamination of soil with human feces. The major species of STH that infect humans are *Ascaris*
38 *lumbricoides* and *Trichuris trichiura* (whipworm), which infect humans via a fecal-oral route, and
39 hookworm (*Anclostoma duodenale* and *Necator americanus*), whose eggs are shed in fecal matter and
40 then hatched larvae burrow through the skin of the host. STH are estimated to infect more than two billion
41 people across the globe [1], and in 2016 caused the loss of an estimated 3.5 million disability-adjusted life
42 years (DALYs) [2].

43 STH affect human health in various ways. Hookworm is known to cause iron deficiency and anemia.
44 For pregnant women, the resulting anemia can be particularly severe [3,4]. Infections with *T. trichiura* are
45 also likely to cause anemia, and are associated with poor growth and delayed cognitive development in
46 children [5]. Infections with *A. lumbricoides* are also associated with poor growth and delayed cognitive
47 development in children [6].

48 Due to the fecal-oral route of transmission and the life stages in the soil, clean water and adequate
49 sanitation access can easily prevent infections with STH [7–9]. However, sanitation access is still limited
50 in lower-income countries, and therefore periodically clearing the parasites with deworming treatments is
51 a short term intervention recommended by the WHO in STH endemic areas. The WHO manages a global
52 donation of anthelmintics (albendazole and mebendazole) —with the support of several pharmaceutical
53 companies who donate the medicines—providing them to endemic countries that request them for control
54 programs targeting preschool children and school-age children. The effectiveness of deworming children
55 has been called into question, however, due to recent reviews finding contradictory results of the health
56 impact of mass drug administration in these populations [10–12]. A recent Cochrane review has also
57 found limited evidence that deworming medicine during antenatal impacts birth outcomes or neonatal
58 mortality [13]. However, the review evaluated less than 4,000 pregnancies in four studies, and the
59 authors state that more data are needed to establish the benefit of the intervention or potential lack thereof.

60 Objectives

61 In this study, we explore the connection between anthelmintic treatment of pregnant women during
62 antenatal care and the outcomes of neonatal mortality and low-birth weight using a retrospective cohort of
63 survey data of more than 770,000 births across a broad range of STH transmission settings.

64 Methods

65 Study design

66 We utilized birth histories from cross-sectional surveys to create a retrospective cohort to measure the
67 impact of routine deworming medicine during antenatal care on subsequent neonatal mortality and low
68 birthweight for births between 1998-2018 in 56 lower income countries (Figure 1).

69 Data sources

70 The Demographic and Health Surveys (DHS) are funded at least in part by the United States Agency
71 for International Development. These surveys utilize nationally representative two-stage cluster samples
72 to generate information on child mortality and women's fertility. As part of the survey, complete birth
73 histories are recorded for all women aged 15-49 years of age, including whether or not each child is still
74 alive and the age of the child's death if the child died. Additionally, information on the most recent
75 pregnancy within the previous 2 years is collected, including various aspects of the woman's antenatal
76 care (ANC) such as a question on the administration of deworming during the most recent pregnancy. We
77 sought to include all DHS datasets with the following conditions: 1) the survey was conducted in 1990 or
78 after, 2) the survey contained information on deworming during ANC, and 3) the survey was publicly
79 available as of August 23, 2019.

80 Outcomes

81 Neonatal mortality served as the primary outcome. In the DHS questionnaire, the survey respondent
82 classifies the age of their child at death in terms of days, weeks, or months. Significant heaping of
83 neonatal mortality occurs at one month of life in these data. We included children as neonatal deaths if
84 their mother described them dying within the first 28 days of life, the first four weeks of life, or the first
85 month of life.

86 Low birthweight served as the secondary outcome. In the DHS questionnaire, a child's weight at birth
87 is included if the child is weighed at birth (approximately 50% of babies in the DHS are weighed at birth).
88 The mother is also asked the child's perceived birth size. We created a composite indicator of measured
89 low birthweight when available and perceived birth size when measured low birthweight was unavailable.
90 For those children who were weighed at birth we categorized children as being low birth weight if they
91 were < 2500 grams at birth. For those children who were not weighed at birth, we categorized children as
92 low birth weight if they were perceived to be smaller than average or very small. We also conducted a
93 sensitivity analysis wherein we limited the low birthweight analyses to those children who were weighed
94 at birth.

95 Bias

96 Women who attend routine antenatal care and receive deworming medicines are predisposed to have
97 better birth outcomes than women who do not, independent of the effect of the deworming medicine. This
98 may include, among other factors, better ANC as well as better post-natal care. We therefore utilized an
99 exact matching procedure to pre-process the data and reduce the selection bias of receiving deworming
100 medicine [14]. We exactly matched women on their probability of receiving deworming during pregnancy
101 using the MatchIt package in R version 3.6.1 [15,16]. The following equation describes the matching
102 process:

$$Deworming_{ijk} = ANC_{ijk} + E_{ijk} + W_{jk} + S_k$$

103 where $Deworming_{ijk}$ is a dichotomous outcome for woman i in household j in survey k ; ANC_{ijk} is a vector
104 of various aspects of ANC, including being weighed during ANC, being measured during ANC, having
105 blood pressure taken during ANC, giving a urine sample during ANC, giving a blood sample during
106 ANC, receiving intermittent preventive treatment for malaria during ANC, and receiving a neonatal
107 tetanus vaccination during ANC; E_{ijk} is whether the woman completed primary education or not; W_{jk} is
108 whether or not house j is rich or poor; and S_k is the survey dataset.

109 Statistical methods

110 We modeled neonatal mortality as a function of receiving deworming medicine during ANC after
111 adjusting for the following *a priori* determined covariates: the mother's age (categorized as < 18, 18-35,
112 and >35), the mother's parity and birth order (categorized as firstborn, 2nd or 3rd born with < 24 months
113 preceding birth interval, 2nd or 3rd born with \geq 24 months preceding birth interval, 4th or later born with <
114 24 months preceding birth interval, and 4th or later born with \geq 24 months preceding birth interval), the
115 presence of a skilled birth attendant during childbirth (doctor, nurse, or midwife), the location of child
116 birth (at a health center or not), the household wealth quintile, the mother's education (categorized as no
117 education, some primary, or completed primary or higher), the location of the house (urban or rural), the
118 household's sanitation access (categorized as any or none), and the survey dataset. We utilized a Poisson
119 model with the number of days alive (up to 28) included as the exposure and the matched group included
120 as a random intercept. The analysis of neonatal mortality can be described using the following equation:

$$121 \mu_{ijkl} = e^{\ln(t_{ijkl}) + \beta_1 Deworming_{ijk} + \chi M_{ijk} + \delta H_{jk} + \kappa S_k + \zeta_l}$$

$$\zeta_l \sim N(0, \psi)$$

122 where μ_{ijkl} is the rate of death for child i in house j in survey k in matched group l , t_{ijkl} is the number of
123 days the child was alive or at risk of death, $Deworming_{ijk}$ is whether or not the child's mother received
124 deworming during ANC, M_{ijk} is a vector of a child's mother's characteristics, H_{jk} is a vector a child's

125 household's characteristics, S_k is a vector of survey characteristics and ζ_l is a random intercept for
126 matched group l that is assumed to be normally distributed with a mean of zero.

127 We modeled low birth weight as a function of receiving deworming medicine during ANC after
128 adjusting for the same *a priori* determined covariates as previously described. We utilized a logit model
129 with the matched group included as a random intercept. The analysis of low birth weight can be described
130 using the following equation:

$$y_{ijkl} | \pi_{ijkl} \sim \text{Binomial}(1, \pi_{ijkl})$$
$$\text{logit}(\pi_{ijkl}) = \beta_1 \text{Deworming}_{ijk} + \chi M_{ijk} + \delta H_{jk} + \kappa S_k + \zeta_l$$
$$\zeta_l \sim N(0, \psi)$$

131 where π_{ijkl} is a dichotomous outcome for child i in household j in survey k in matched group l ,
132 Deworming_{ijk} is whether the child's mother received deworming medicine during ANC, M_{ijk} is a
133 vector of a child's mother's characteristics, H_{jk} is a vector of a child's household's characteristics, S_k is a
134 vector of survey characteristics and ζ_l is a random intercept for matched group l that is assumed to be
135 normally distributed with a mean of zero. All analyses were conducted in Stata version 15.1.

136 We also tested whether the association between deworming medicine and the outcomes of neonatal
137 mortality and low birthweight was moderated by the prevalence of any STH in the country. Based upon
138 estimates provided by Pullan et al. [17], we categorized countries as being low (< 20%) or high (> 20%)
139 STH prevalence and then tested for an interaction between low/high STH prevalence and receiving
140 deworming during ANC using a likelihood ratio test of the log likelihoods.

141 Findings

142 Participants

143 As of October 2019, a total of 290 survey datasets listed at www.dhsprogram.com contained
144 information on either neonatal mortality, low birthweight, or deworming during ANC. Deworming during
145 ANC was available for 95 of these datasets. One survey dataset (Rwanda 2007-08) did not have measures
146 of low birth weight. This left 95 datasets available to create a retrospective cohort of 825,492 single live
147 births to assess the impact of deworming during ANC on neonatal mortality and 94 datasets available to
148 create a retrospective cohort of 807,957 single live births to assess the impact of deworming during ANC
149 on low birthweight. Following exact matching, 95 datasets and 797,772 women were available for the
150 outcome of neonatal mortality and 94 datasets and 772,155 women were available for the outcome of low
151 birthweight. Figure 1 shows the geographic distribution of countries included in the analyses.



152

153 *Figure 1: Map showing the countries included in the analyses.*

154 **Descriptive data**

155 Among matched births, 25% of mothers reported receiving deworming medicine during ANC. Two
 156 percent of births resulted in a neonatal death ($n = 15,784$). Only 61% ($n = 487,763$) of mothers reported a
 157 measured birthweight. Among births with a measured birthweight, 12.5% ($n = 61,177$) were < 2500
 158 grams. Mean birthweight was 3,072g (standard deviation = 691g). Among 770,300 births with a
 159 perceived birth size, 93,802 mothers (12%) reported the baby to be “smaller than average” and 39,601
 160 mothers reported the baby to be “very small” (5%). Table 1 provides dataset-level information on
 161 deworming during ANC and birth outcomes.

162 *Table 1: Number of women receiving deworming medicine during routine ANC and birth outcomes.*

Survey dataset	Coverage of deworming during ANC	Neonatal deaths without deworming / N without deworming	Neonatal deaths with deworming / N with deworming	LBW without deworming / N without deworming	LBW with deworming / N with deworming
Afghanistan 2015	3%	396 / 17,773	20 / 616	3,800 / 17,355	136 / 605
Albania 2008-09	3%	6 / 933	0 / 31	30 / 930	0 / 31
Albania 2017-18	2%	2 / 1952	0 / 45	79 / 1,950	2 / 45
Angola 2015-16	46%	113 / 4,607	69 / 3,939	514 / 4,262	365 / 3,855
Armenia 2010	1%	5 / 1,136	0 / 7	70 / 1,134	1 / 7
Azerbaijan 2006	3%	31 / 1,430	1 / 51	123 / 1,201	8 / 47
Benin 2011-12	76%	44 / 2,066	97 / 6,397	282 / 1,829	766 / 6,205
Benin 2017-18	66%	66 / 2,841	122 / 5,578	379 / 2,801	616 / 5,529
Burkina Faso 2010	26%	138 / 7,471	32 / 2,562	1,025 / 7,456	299 / 2,559
Burundi 2010-11	31%	85 / 3,339	29 / 1,1519	445 / 3,281	155 / 1,503
Burundi 2016-17	66%	31 / 2,888	93 / 5,708	361 / 2,879	582 / 5,697
Cambodia 2005	12%	125 / 4,979	9 / 700	740 / 4,940	84 / 692
Cambodia 2010	50%	74 / 3,105	45 / 3,106	344 / 2,969	226 / 3,051
Cambodia 2014	74%	24 / 1,442	47 / 4,212	157 / 1,428	330 / 4,200
Cameroon 2011	43%	86 / 4,090	58 / 3,069	579 / 4,059	299 / 3,053
Chad 2014-15	23%	185 / 8,076	44 / 2,382	2,362 / 8,011	508 / 2,376
Comoros 2012	60%	19 / 722	18 / 1,077	178 / 685	209 / 1,048

Congo 2011-12	81%	22 / 1,167	71 / 4,888	145 / 1,128	469 / 4,858
Cote d'Ivoire 2011	38%	96 / 3,110	43 / 1,877	447 / 3,024	271 / 1,851
DRC 2013-14	52%	121 / 5,190	107 / 5,724	451 / 5,075	470 / 5,667
Dominican Republic 2013	13%	41 / 2,478	4 / 354	345 / 2,472	46 / 354
Egypt 2014	4%	85 / 9,981	3 / 397	1,413 / 9,968	51 / 393
Eswatini 2006-07	12%	37 / 1,583	5 / 212	121 / 1,557	15 / 207
Ethiopia 2011	6%	176 / 7,099	15 / 422	2,283 / 7081	120 / 422
Ethiopia 2016	6%	149 / 6,438	10 / 415	1,668 / 6,366	95 / 411
Gabon 2012	64%	27 / 1,416	44 / 2,495	218 / 1,302	323 / 2,434
Gambia 2013	43%	38 / 2,947	27 / 2,215	541 / 2,939	300 / 2,211
Ghana 2008	40%	28 / 1,139	14 / 746	136 / 1,130	90 / 743
Ghana 2014	44%	41 / 2,280	31 / 1,800	1,203 / 8,431	89 / 623
Guatemala 2014-15	7%	110 / 8,438	8 / 623	1,203 / 8,431	89 / 623
Guinea 2012	30%	88 / 3,368	23 / 1,473	387 / 3,361	131 / 1,473
Guyana 2009	20%	17 / 1,135	4 / 289	175 / 1,127	41 / 285
Haiti 2005-06	7%	74 / 3,566	9 / 286	1,083 / 3,566	78 / 286
Haiti 2012	15%	104 / 4,294	16 / 785	1,331 / 4,288	199 / 785
Haiti 2016-17	10%	100 / 4,102	7 / 477	991 / 4,102	99 / 477
Honduras 2005-06	8%	78 / 6,632	11 / 547	1,101 / 6,625	108 / 544
Honduras 2011-12	7%	92 / 7,687	12 / 612	1,069 / 7,681	97 / 612
India 2005-06	4%	782 / 34,248	26 / 1,433	7,304 / 33,761	284 / 1,422
India 2015-16	15%	3,504 / 159,219	468 / 29,185	25,971 / 155,748	4,785 / 28,940
Kenya 2008	20%	57 / 2,770	13 / 672	348 / 2,747	54 / 668
Kenya 2014	31%	66 / 4,744	41 / 2,179	549 / 4,679	202 / 2,172
Liberia 2007	30%	62 / 2,600	20 / 1,108	539 / 2,592	180 / 1,106
Liberia 2013	57%	55 / 2,230	61 / 2,978	459 / 2,228	543 / 2,971
Madagascar 2008-09	40%	93 / 4,984	47 / 3,373	916 / 4,911	531 / 3,320
Malawi 2010	28%	209 / 9,518	78 / 3,759	1,176 / 9,375	469 / 3,706
Malawi 2015-16	52%	123 / 6,289	115 / 6,816	780 / 6,245	841 / 6,781
Maldives 2009	18%	17 / 2,482	0 / 552	261 / 2,481	61 / 552
Mali 2012-13	29%	120 / 4,461	42 / 1,847	732 / 4,225	225 / 1,818
Mali 2018	49%	83 / 3,108	60 / 2,941	524 / 2,787	571 / 2,875
Mozambique 2011	33%	137 / 4,804	66 / 2,390	593 / 4,594	286 / 2,352
Myanmar 2015-16	57%	33 / 1,614	32 / 2,127	214 / 1,531	223 / 2,079
Namibia 2006-07	8%	58 / 3,293	6 / 289	460 / 3,261	48 / 281
Namibia 2013	7%	52 / 3,337	4 / 265	439 / 3,310	34 / 262
Nepal 2006	19%	80 / 3,276	15 / 786	639 / 3,274	139 / 786
Nepal 2011	59%	33 / 1,629	42 / 2,353	302 / 1,627	379 / 2,352
Nepal 2016	74%	21 / 1,021	28 / 2,910	163 / 1,020	402 / 2,905
Niger 2012	51%	64 / 3,705	65 / 3,793	854 / 3,490	810 / 3,748
Nigeria 2008	10%	440 / 15,188	36 / 1,656	2,379 / 15,062	172 / 1,650
Nigeria 2013	16%	465 / 16,073	91 / 3,001	2,445 / 15,971	315 / 2,991
Pakistan 2012-13	2%	235 / 6,136	5 / 156	1,340 / 6,123	38 / 156
Pakistan 2017-18	2%	194 / 6,823	2 / 163	1,344 / 6,804	32 / 159
Peru 2004-08	4%	79 / 8,864	1 / 348	898 / 8,858	38 / 348
Peru 2009	3%	72 / 7,871	1 / 280	750 / 7,866	30 / 280
Peru 2010	3%	59 / 7,056	1 / 253	687 / 7,055	32 / 253
Peru 2011	3%	60 / 6,967	2 / 251	646 / 6,966	28 / 251
Peru 2012	3%	60 / 6,887	1 / 243	576 / 6,84	28 / 243
Philippines 2008	5%	45 / 4,011	3 / 196	823 / 3,999	54 / 196

Philippines 2013	5%	44 / 4,571	5 / 263	782 / 3,719	48 / 214
Philippines 2017	7%	85 / 7,016	5 / 498	837 / 5,939	68 / 423
Rwanda 2007-08	19%	43 / 2,567	9 / 617	.	.
Rwanda 2010	40%	62 / 3,754	34 / 2,453	348 / 3,742	178 / 2,443
Rwanda 2014-15	50%	44 / 2,934	37 / 2,945	217 / 2,923	179 / 2,934
STP 2008	59%	6 / 551	7 / 794	45 / 537	52 / 770
Senegal 2010-11	25%	141 / 5,656	51 / 1,927	1,143 / 5,641	388 / 1,922
Senegal 2012-13	28%	59 / 2,823	17 / 1,107	697 / 2,821	236 / 1,105
Senegal 2014	30%	110 / 5,664	32 / 2,411	1,406 / 5,662	512 / 2,409
Senegal 2015	32%	54 / 2,903	31 / 1,369	672 / 2,902	234 / 1,368
Senegal 2016	35%	66 / 2,698	19 / 1,466	642 / 2,697	241 / 1,462
Senegal 2017	44%	107 / 4,290	72 / 3,380	891 / 4,286	670 / 3,374
Sierra Leone 2008	47%	61 / 1,945	57 / 1,720	325 / 1,913	283 / 1,687
Sierra Leone 2013	74%	79 / 2,110	198 / 6,140	326 / 2,050	675 / 6,038
Tajikistan 2017	2%	45 / 4,000	0 / 83	296 / 3,867	10 / 79
Tanzania 2015-16	63%	47 / 2,563	74 / 4,306	273 / 2,542	362 / 4,284
Timor-Leste 2009-10	14%	97 / 4,918	10 / 832	727 / 4,813	110 / 831
Timor-Leste 2016	18%	61 / 3,931	19 / 840	358 / 3,252	60 / 763
Togo 2013-14	62%	38 / 1,807	57 / 2,920	287 / 1,789	292 / 2,904
Uganda 2006	27%	63 / 3,464	23 / 1,293	648 / 3,435	203 / 1,289
Uganda 2011	51%	69 / 2,326	39 / 2,375	414 / 2,281	324 / 2,321
Uganda 2016	61%	112 / 3,888	110 / 6,129	574 / 3,800	692 / 6,050
Ukraine 2007	7%	4 / 960	1 / 75	33 / 960	7 / 75
Yemen 2013	3%	174 / 9,776	8 / 352	3,109 / 9,756	137 / 351
Zambia 2007	39%	69 / 2,293	31 / 1,450	237 / 2,273	109 / 1,444
Zambia 2013	66%	56 / 3,038	84 / 6,004	335 / 3,008	527 / 5,941
Zimbabwe 2010-11	3%	59 / 3,211	1 / 103	279 / 3,164	10 / 103
Zimbabwe 2015	3%	63 / 4,152	3 / 145	391 / 4,145	9 / 145

163

164 Main results

165 Before adjusting for any other covariates, 2.1% of births where mothers did not receive deworming
 166 during ANC (12,873 / 610,118) and 1.8% of births where mothers did receive deworming (3,622 /
 167 202,501) during ANC died within the neonatal period (relative risk of cumulative incidence = 0.85).

168 Before adjusting for any other covariates, 16.9% of babies where mothers did not receive deworming
 169 during ANC (102,802 / 505,383) and 13.3% babies where mothers did receive deworming during ANC
 170 (26,590 / 199,772) were considered low birth weight (relative risk of cumulative incidence = 0.79).

171 After adjusting for selection bias via exact matching and including other factors hypothesized to be
 172 associated with neonatal mortality, receiving deworming during routine ANC was associated with a 14%
 173 reduction in the risk of neonatal mortality (IRR = 0.86, 95% CI = 0.82 – 0.90) (Table 2). This relationship
 174 was not moderated by STH prevalence: the likelihood ratio test for interaction was not statistically
 175 significant (likelihood ratio [LR] = 2.19, p = 0.139).

176

177 *Table 2: Results from Poisson regression analysis of deworming during ANC and neonatal mortality.*

Measure	Categorization	Unadjusted IRR (95% CI)	P-value	Adjusted IRR (95% CI)	P-value
Deworming	No deworming during ANC	Ref.	Ref.	Ref.	Ref.
	Deworming during ANC	0.81 (0.78 – 0.85)	< 0.001	0.86 (0.82 – 0.89)	< 0.001
Skilled birth attendant	No doctor, nurse, or midwife during delivery	Ref.	Ref.	Ref.	Ref.
	Doctor, nurse, or midwife during delivery	0.91 (0.88 – 0.94)	< 0.001	1.01 (0.94 – 1.08)	0.767
Facility delivery	Child was delivered somewhere other than a health center	Ref.	Ref.	Ref.	Ref.
	Child was delivered at a health center	0.92 (0.89 – 0.95)	< 0.001	1.11 (1.04 – 1.19)	0.002
Mother's age at delivery	18-35 years old	Ref.	Ref.	Ref.	Ref.
	< 20 years old	1.31 (1.25 – 1.38)	< 0.001	1.18 (1.11 – 1.24)	< 0.001
	> 35 years old	1.59 (1.52 – 1.66)	< 0.001	1.59 (1.52 – 1.66)	< 0.001
Mother's parity	Child is firstborn	Ref.	Ref.	Ref.	Ref.
	2 nd born ≥ 24 month preceding birth interval	0.67 (0.64 – 0.71)	< 0.001	0.69 (0.65 – 0.73)	< 0.001
	2 nd born < 24 month preceding birth interval	0.91 (0.85 – 0.98)	0.013	0.91 (0.85 – 0.98)	0.002
	3 rd born or later ≥ 24 month preceding birth interval	0.90 (0.86 – 0.93)	< 0.001	0.78 (0.74 – 0.82)	< 0.001
	3 rd born or later < 24 month preceding birth interval	1.45 (1.38 – 1.52)	< 0.001	1.30 (1.23 – 1.38)	< 0.001
Mother's education	No education	Ref.	Ref.	Ref.	Ref.
	Some primary school	0.95 (0.90 – 0.99)	0.022	1.02 (0.97 – 1.07)	0.488
	Completed primary school	0.93 (0.88 – 0.99)	0.020	1.02 (0.95 – 1.10)	0.529
	Some secondary school or higher	0.71 (0.68 – 0.74)	< 0.001	0.87 (0.82 – 0.92)	< 0.001
Household location	Rural	Ref.	Ref.	Ref.	Ref.
	Urban	1.14 (1.10 – 1.18)	< 0.001	0.97 (0.93 – 1.01)	0.139
Sanitation access	Any type of sanitation access	Ref.	Ref.	Ref.	Ref.
	No sanitation access	1.29 (1.24 – 1.33)	< 0.001	1.13 (1.09 – 1.18)	< 0.001
Household wealth	Poorest wealth quintile	Ref.	Ref.	Ref.	Ref.
	Poorer wealth quintile	0.98 (0.94 – 1.03)	0.403	1.04 (0.99 – 1.09)	0.120
	Middle wealth quintile	0.90 (0.86 – 0.94)	< 0.001	1.05 (0.99 – 1.10)	0.105
	Richer wealth quintile	0.82 (0.78 – 0.86)	< 0.001	1.01 (0.95 – 1.08)	0.743
	Richest wealth quintile	0.69 (0.66 – 0.73)	< 0.001	0.92 (0.85 – 0.99)	0.024

178 N = 797,771 children, 7,255 matched groups (adjusted model only), 95 survey datasets ranging from year
 179 2005-2018. Unadjusted model standard errors were adjusted for survey cluster and included survey

180 dataset as a covariate. Adjusted model included a random intercept of matched group and survey dataset
 181 as a covariate.

182 After adjusting for selection bias via exact matching and including other factors hypothesized to be
 183 associated with low birthweight, receiving deworming during routine ANC was associated with a 6%
 184 reduction in the odds of low birthweight (Odds ratio [OR] = 0.94, 95% CI = 0.92 – 0.95). This
 185 relationship was moderated by STH prevalence (LR = 23.87, $p < 0.001$). In low transmission countries (<
 186 20% national STH prevalence according to Pullan et al. [17]), deworming during routine ANC was
 187 associated with an 11% reduction in the odds of low birthweight (OR = 0.89, 95% CI = 0.87 – 0.92). In
 188 high transmission countries (> 20% national STH prevalence), deworming during routine ANC was
 189 associated with a 3% reduction in the odds of low birthweight (OR = 0.97, 95% CI = 0.95 – 0.99). Table
 190 3 shows the results from the unadjusted and adjusted analyses of low birthweight.

191

192 *Table 3: Results from logistic regression analysis of deworming during ANC and low birthweight.*

Measure	Categorization	Unadjusted OR (95% CI)	P-value	Adjusted OR (95% CI)	P-value
Deworming	No deworming during ANC and < 20% national prevalence	Ref.	Ref.	Ref.	Ref.
	Deworming during ANC and < 20% national prevalence	0.80 (0.78 – 0.83)	< 0.001	0.89 (0.87 – 0.92)	< 0.001
	No deworming during ANC and > 20% national prevalence	Ref.	Ref.	Ref.	Ref.
	Deworming during ANC and > 20% national prevalence	0.89 (0.87 – 0.91)	< 0.001	0.97 (0.95 – 0.99)	< 0.001
Skilled birth attendant	No doctor, nurse, or midwife during delivery	Ref.	Ref.	Ref.	Ref.
	Doctor, nurse, or midwife during delivery	0.68 (0.67 – 0.69)	< 0.001	0.85 (0.83 – 0.88)	< 0.001
Facility delivery	Child was delivered somewhere other than a health center	Ref.	Ref.	Ref.	Ref.
	Child was delivered at a health center	0.69 (0.68 – 0.71)	< 0.001	0.93 (0.90 – 0.95)	< 0.001
Mother's age at delivery	18-35 years old	Ref.	Ref.	Ref.	Ref.
	< 20 years old	1.30 (1.27 – 1.32)	< 0.001	1.15 (1.12 – 1.17)	< 0.001
	> 35 years old	1.08 (1.06 – 1.11)	< 0.001	1.05 (1.02 – 1.07)	< 0.001
Mother's parity	Child is firstborn	Ref.	Ref.	Ref.	Ref.
	2 nd born \geq 24 month preceding birth interval	0.83 (0.81 – 0.84)	< 0.001	0.82 (0.81 – 0.84)	< 0.001
	2 nd born < 24 month preceding birth interval	0.94 (0.92 – 0.97)	< 0.001	0.90 (0.87 – 0.92)	< 0.001
	3 rd born or later \geq 24	0.91 (0.89 – 0.92)	< 0.001	0.80 (0.79 – 0.82)	< 0.001

	month preceding birth interval				
	3 rd born or later < 24 month preceding birth interval	0.99 (0.97 – 1.01)	0.372	0.86 (0.84 – 0.88)	< 0.001
Mother's education	No education	Ref.	Ref.	Ref.	Ref.
	Some primary school	0.89 (0.87 – 0.91)	< 0.001	0.90 (0.88 – 0.92)	< 0.001
	Completed primary school	0.77 (0.75 – 0.79)	< 0.001	0.80 (0.77 – 0.82)	< 0.001
	Some secondary school or higher	0.67	< 0.001	0.73 (0.71 – 0.75)	< 0.001
Household location	Rural	Ref.	Ref.	Ref.	Ref.
	Urban	1.26 (1.24 – 1.28)	< 0.001	0.95 (0.94 – 0.97)	< 0.001
Sanitation access	Any type of sanitation access	Ref.	Ref.	Ref.	Ref.
	No sanitation access	1.32 (1.30 – 1.34)	< 0.001	1.10 (1.08 – 1.12)	< 0.001
Household wealth	Poorest wealth quintile	Ref.	Ref.	Ref.	Ref.
	Poorer wealth quintile	0.83 (0.82 – 0.85)	< 0.001	0.90 (0.88 – 0.92)	< 0.001
	Middle wealth quintile	0.74 (0.73 – 0.76)	< 0.001	0.82 (0.80 – 0.84)	< 0.001
	Richer wealth quintile	0.68 (0.67 – 0.70)	< 0.001	0.80 (0.78 – 0.83)	< 0.001
	Richest wealth quintile	0.56 (0.55 – 0.58)	< 0.001	0.72 (0.69 – 0.74)	< 0.001

193 N = 781,352 children, 7,170 matched groups (adjusted model only), 94 survey datasets ranging from year
 194 2005-2018. Unadjusted model standard errors were adjusted for survey cluster and included survey
 195 dataset as a covariate. Adjusted model included a random intercept of matched group and survey dataset
 196 as a covariate.

197 Among the children who were weighed at birth, the effect of deworming during ANC on low
 198 birthweight was somewhat smaller (OR = 0.97, 95% CI = 0.95 – 1.00, p = 0.022). There was also a
 199 significant interaction between STH prevalence and receipt of deworming medicine during ANC (LR
 200 10.28, p = 0.0013). Deworming during ANC effectively reduced the odds of low birth weight in low
 201 transmission countries (OR = 0.93, 95% CI = 0.89 – 0.96), but not in high transmission countries (OR =
 202 1.00, 95% CI = 0.97 – 1.03).

203 Interpretation

204 Key results

205 We provide empirical evidence as to the impact of deworming in pregnant women on the neonatal
 206 health of their infants (low birthweight and neonatal mortality) across a large range of STH endemic
 207 countries. Using a retrospective birth cohort of more than 770,000 births, we find that children born to
 208 mothers who received deworming during antenatal care have a 14% lower risk of neonatal mortality (95%
 209 CI = 11 – 16%). In countries with < 20% estimated national prevalence of any STH, deworming during
 210 antenatal care was associated with an 11% reduction in the odds of low birthweight (95% CI = 8 – 13%).

211 In countries with > 20% estimated national prevalence of any STH, deworming during ANC was
212 associated with a 3% reduction in the odds of low birthweight (95% CI = 1-5%).

213 Limitations

214 A number of limitations are present in this analysis. First, there is selection bias in women receiving
215 deworming during ANC. Due to the inequity observed in children receiving deworming medicines [18],
216 we suspect that mothers receiving deworming during ANC are predisposed to have better birth outcomes
217 than mothers not receiving deworming during ANC. We have attempted to mitigate the selection bias by
218 matching mothers on the probability that they receive deworming during ANC before analysis. There may
219 still be some residual confounding in this analysis. Second, this study relies on mothers' recall of
220 medicines received during their most recent pregnancy. There may be some recall error associated with
221 mothers' abilities to remember all the medicines and supplements they received during pregnancy, and
222 recall bias may be present if mothers of babies suffering neonatal deaths are more likely remember
223 receiving deworming medicine or not better than mothers of surviving babies. We have attempted to
224 mitigate this limitation by only including the most recent pregnancy and only including pregnancies
225 within 5 years of the study. Third, because this study creates a retrospective cohort from historical birth
226 outcomes we are unable to account for the mother's or child's health status at the time of pregnancy and
227 birth. Fourth, this study relies on mothers' recall of the age of the child at death, which may lead to
228 misclassification error in our outcome of neonatal mortality. As such, we observed heaping of death at
229 one month of age. We have chosen to include children dying at one month of age as neonatal deaths. We
230 do not expect the misclassification error to be related to receiving deworming during ANC and suspect no
231 bias in this regard. And fifth, our measure of low birthweight is a composite indicator of a mother's
232 perception of birth size or a mother's recall of the child's birth weight if the child was weighed at birth.
233 This approach may lead to misclassification error in our outcome of low birth weight, but we do not
234 expect it to bias the results as it is not likely to be associated with receiving deworming medicine during
235 ANC. There were also no differences in the results when we limited the analysis to those babies who were
236 weighed at birth.

237 Interpretation

238 These results suggest a strong benefit of deworming during ANC that is perhaps even more
239 pronounced in low transmission areas. The half-life of deworming medicines is quite short (< 24 hours),
240 and very little chemoprophylaxis is provided for women treated. Reinfection occurs rapidly in areas of
241 high transmission, particularly among those who were previously infected [19,20]. Deworming should
242 only be considered a stopgap measure, useful to reduce harm from STH infections as the world pursues
243 universal access to improved sanitation. However, deworming should be available to all pregnant women

244 in STH-endemic countries, given the increased risk of low birthweight and neonatal mortality when living
245 in communities where access to sanitation is limited [21].

246 Periodic deworming is a very low-cost intervention. Where infrastructure for distribution is in place,
247 such as through school programs, vaccination campaigns or routine ANC, the intervention cost is a few
248 cents for each individual treated [22,23]. Considered safe during pregnancy, the risk of side effects from
249 the drug administration is also minimal because benzimidazoles are poorly absorbed and are normally
250 expelled after killing the worms present in the intestine [24]. These results provide impetus to improve
251 access to deworming medicines during routine ANC.

252 While some have called for randomized trials of deworming for pregnant women to establish efficacy,
253 these results suggest that deworming reduces the risk of neonatal mortality and low birthweight. To our
254 knowledge this is the largest analysis conducted on deworming and birth outcomes (more than 770,000
255 births – previous Cocherane review has < 3,400), and in our view is the more appropriate approach to
256 provide evidence on a relatively rare event like neonatal mortality. From an empirical perspective, a
257 sample size of 3,400 does not allow for a great deal of variation in the outcome variable. That is, for low
258 probability (p) events, np is typically low unless n is sufficiently large to compensate. The approach we
259 used herein also avoids the ethical dilemma of withholding an intervention from the control group, the
260 major limitation to conducting randomized control trials of clearing parasites with deworming medicine.

261 The WHO recommends periodic deworming of children and women of reproductive age (including
262 pregnant women after the first trimester) [24]. While in the last 10 years the coverage of the intervention
263 scaled up significantly for preschool and school age children, reaching over 65% in 2017 [25], the scale
264 up of coverage for women of reproductive age has been much slower, with an average of 23% of pregnant
265 women in STH endemic countries receiving deworming during ANC [26]. A recent meeting of the WHO
266 Advisory Group on deworming in girls and women of reproductive age [27] urged all stakeholders in
267 women's health to take immediate action in their respective domains to ensure that women of
268 reproductive age are now included in their STH policies and programs, and to invite WHO to develop
269 support material to facilitate implementation of deworming programs [28].

270 The traditional understanding of host-parasite interactions during pregnancy is that the parasite takes
271 nutrients from the pregnant host, that either causes anemia and/or reduces the nutrients passing to the
272 fetus leading to intrauterine growth restriction [29,30], increased risk of low birthweight, and then
273 subsequent neonatal mortality [31]. In this analysis, the impact of deworming on low birthweight was
274 quite modest in high transmission areas (3% reduction) compared to the impact of deworming on neonatal
275 mortality (14% reduction). These results provide some evidence that helminth infections may indeed
276 decrease nutrient flow to the fetus, but perhaps raise questions about other ways in which helminth
277 infections affect pregnancy.

278 We suspect the primary mechanism of protection for deworming medicines to be through improving
279 the health of the mother and subsequently the health of the fetus. In order to survive within their hosts,
280 STH modify their hosts' immune responses, downregulating T-cell activity and other immune responses
281 [32]. This immunosuppression affects not only the hosts' immune response to the STH, but also the
282 immune response to other pathogens. For example, chronic STH infection is associated with suboptimal
283 immunity following the receipt of various vaccines [33]. And, in areas of high prevalence of STH, routine
284 deworming led to improved immune responses to non-STH pathogens [34]. This effect of compromising
285 maternal immunity may be particularly serious given that a pregnant woman's immune response is
286 downregulated by the 18th week of fetal gestation to ensure the mother's body does not reject the fetus as
287 a foreign body [35,36]. Furthermore, immune system downregulation passes through to the fetus.
288 Helminth infections prime the immune system of the fetus, making children born to mothers with
289 helminth infections more vulnerable to not only helminth infections after they are born, but other
290 pathogens as well [37,38]. This mechanism could lead to increased risk of neonatal mortality for children
291 of women who do not receive deworming medicines during antenatal care.

292 Conclusion

293 This large retrospective cohort of survey data suggests that deworming during antenatal care provides
294 a protective benefit against neonatal mortality and low birthweight. This protection is even greater in
295 countries with lower STH transmission.

296 Other information

297 Funding

298 The authors received no funding for this study, but are open to suggestions about how to fund their
299 work.

300 Author contributions

301 Conceptualization, DAL; Methodology, BW, BK, DAL; Formal analysis, DAL; Data curation, BK,
302 DAL; Writing – original draft, BW, DAL; Writing – review and editing, BW, BK, SL, TE, AM DAL;
303 Visualization, DAL; Supervision, BK, DAL; Project administration, BK, DAL.

304 Acronyms

305 ANC = antenatal care

306 CI = confidence interval

307 DHS = demographic health survey

308 IRR = incident rate ratio

309 LR = likelihood ratio

310 OR = odds ratio

311 References

- 312 1. De Silva NR, Brooker S, Hotez PJ, Montresor A, Engels D, Savioli L. Soil-transmitted helminth
313 infections: Updating the global picture. *Trends Parasitol.* 2003;19: 547–551.
314 doi:10.1016/j.pt.2003.10.002
- 315 2. World Health Organization. Global health estimates 2016: Disease burden by cause, age, sex, by
316 country and by region, 2000-2016. Geneva, Switzerland; 2018.
- 317 3. Gyorkos TW, Gilbert NL, Pasricha S, Drakesmith H, Black J, Hipgrave D, et al. Blood Drain:
318 Soil-Transmitted Helminths and Anemia in Pregnant Women. Garba A, editor. *PLoS Negl Trop*
319 *Dis. Public Library of Science*; 2014;8: e2912. doi:10.1371/journal.pntd.0002912
- 320 4. Larocque R, Casapia M, Gotuzzo E, Gyorkos TW. Relationship between intensity of soil-
321 transmitted helminth infections and anemia during pregnancy. *Am J Trop Med Hyg.* 2005;73:
322 783–9.
- 323 5. Stephenson LS, Holland CV, Cooper ES. The public health significance of *Trichuris trichiura*.
324 *Parasitology.* 2000;121: S73–S95. doi:10.1017/s0031182000006867
- 325 6. O’Lorcain P, Holland CV. The public health importance of *Ascaris lumbricoides*. *Parasitology.*
326 *Syracuse University Libraries*; 2000;121: S51–S71. doi:10.1017/s0031182000006442
- 327 7. Asaolu S., Ofoezie I. The role of health education and sanitation in the control of helminth
328 infections. *Acta Trop.* 2003;86: 283–294. doi:10.1016/S0001-706X(03)00060-3
- 329 8. Strunz EC, Addiss DG, Stocks ME, Ogden S, Utzinger J, Freeman MC. Water, Sanitation,
330 Hygiene, and Soil-Transmitted Helminth Infection: A Systematic Review and Meta-Analysis.
331 Hales S, editor. *PLoS Med. Public Library of Science*; 2014;11: e1001620.
332 doi:10.1371/journal.pmed.1001620
- 333 9. Ziegelbauer K, Speich B, Mäusezahl D, Bos R, Keiser J, Utzinger J. Effect of sanitation on soil-
334 transmitted helminth infection: systematic review and meta-analysis. *PLoS Med.* 2012;9:
335 e1001162. doi:10.1371/journal.pmed.1001162
- 336 10. Ahuja A, Baird S, Hicks JH, Kremer M, Miguel E, Powers S. Invited papers: When should
337 governments subsidize health? The case of mass deworming. *World Bank Econ Rev.* 2015;29: S9–
338 S24. doi:10.1093/wber/lhv008
- 339 11. Welch VA, Ghogomu E, Hossain A, Awasthi S, Bhutta ZA, Cumberbatch C, et al. Mass
340 deworming to improve developmental health and wellbeing of children in low-income and middle-
341 income countries: a systematic review and network meta-analysis. *Lancet Glob Heal.* The
342 Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license;
343 2017;5: e40–e50. doi:10.1016/S2214-109X(16)30242-X
- 344 12. Croke K, Hicks JH, Hsu E, Kremer M, Miguel E. Does Mass Deworming Affect Child Nutrition?
345 Meta-Analysis, Cost-Effectiveness, and Statistical Power. *Policy Res Work Pap.* 2016;7921.
- 346 13. Salam RA, Haider BA, Humayun Q, Bhutta ZA. Effect of administration of antihelminthics for
347 soil-transmitted helminths during pregnancy. *Cochrane Database Syst Rev.* 2015;2015.
348 doi:10.1002/14651858.CD005547.pub3
- 349 14. Ho DE, Imai K, King G, Stuart EA. Matching as Nonparametric Preprocessing for Reducing
350 Model Dependence in Parametric Causal Inference. *Polit Anal.* 2007;15: 199–236. Available:
351 <http://gking.harvard.edu/files/abs/matchp-abs.shtml>
- 352 15. Ho D, Imai K, King G, Stuart EA. MatchIt: Nonparametric preprocessing for parametric causal
353 inference. *Citeseer.* 2007; Available:
354 <http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.138.698&rep=rep1&type=pdf>
- 355 16. R Core Development Team. R: A Language and Environment for Statistical Computing.
356 <http://www.R-project.org/>. R Foundation for Statistical Computing; 2010;
- 357 17. Pullan RL, Smith JL, Jasrasaria R, Brooker SJ. Global numbers of infection and disease burden of

- 358 soil transmitted helminth infections in 2010. *Parasites and Vectors*. 2014;7: 1–19.
359 doi:10.1186/1756-3305-7-37
- 360 18. Lo NC, Heft-Neal S, Coulibaly JT, Leonard L, Bendavid E, Addiss DG. State of deworming
361 coverage and equity in low-income and middle-income countries using household health surveys:
362 a spatiotemporal cross-sectional study. *Lancet Glob Heal*. The Author(s). Published by Elsevier
363 Ltd. This is an Open Access article under the CC BY 4.0 license; 2019;7: e1511–e1520.
364 doi:10.1016/s2214-109x(19)30413-9
- 365 19. Jia TW, Melville S, Utzinger J, King CH, Zhou XN. Soil-transmitted helminth reinfection after
366 drug treatment: A systematic review and meta-analysis. *PLoS Negl Trop Dis*. 2012;6.
367 doi:10.1371/journal.pntd.0001621
- 368 20. Zerdo Z, Yohanes T, Tariku B. Soil-Transmitted Helminth Reinfection and Associated Risk
369 Factors among School-Age Children in Chenchu District, Southern Ethiopia: A Cross-Sectional
370 Study. *J Parasitol Res*. Hindawi Publishing Corporation; 2016;2016. doi:10.1155/2016/4737891
- 371 21. Kmush BL, Walia B, Neupane A, Frances C, Mohamed IA, Larsen DA. Does it matter where my
372 neighbor poops? - Community-level impacts of sanitation access on maternal and neonatal health.
373 The 68th Annual Meeting of the American Society of Tropical Medicine and Hygiene. National
374 Harbor, Maryland; 2019.
- 375 22. Boselli G, Yajima A, Aratchige PE, Feldon KE, Xeuatvongsa A, Phounphenghak K, et al.
376 Integration of deworming into an existing immunisation and vitamin A supplementation campaign
377 is a highly effective approach to maximise health benefits with minimal cost in Lao PDR. *Int*
378 *Health*. Royal Society of Tropical Medicine and Hygiene; 2011;3: 240–245.
379 doi:10.1016/j.inhe.2011.08.002
- 380 23. Montresor A, Gabrielli AF, Diarra A, Engels D. Estimation of the cost of large-scale school
381 deworming programmes with benzimidazoles. *Trans R Soc Trop Med Hyg*. 2010;104: 129–132.
382 doi:10.1016/j.trstmh.2009.10.007
- 383 24. World Health Organization. Guideline: preventive chemotherapy to control soil-transmitted
384 helminth infections in at-risk population groups. 2017.
- 385 25. World Health Organization. Schistosomiasis and soil-transmitted helminthiases: number of
386 people treated in 2016. *Wkly Epidemiological Rec*. 2016; 585–595.
- 387 26. Bangert M, Bancalari P, Mupfasoni D, Mikhailov A, Gabrielli AF, Montresor A. Provision of
388 deworming intervention to pregnant women by antenatal services in countries endemic for soil-
389 transmitted helminthiasis. *PLoS Negl Trop Dis*. 2019;13: 7–13. doi:10.1371/journal.pntd.0007406
- 390 27. World Health Organization. Report of the WHO Advisory Group on deworming in girls and
391 women of reproductive age. Geneva, Switzerland; 2018.
- 392 28. Gyorkos TW, Montresor A, Belizario V, Biggs BA, Bradley M, Brooker SJ, et al. The right to
393 deworming: The case for girls and women of reproductive age. *PLoS Negl Trop Dis*. 2018;12: 9–
394 12. doi:10.1371/journal.pntd.0006740
- 395 29. Rodríguez-Morales AJ, Barbella RA, Case C, Arria M, Ravelo M, Perez H, et al. Intestinal
396 parasitic infections among pregnant women in Venezuela. *Infect Dis Obstet Gynecol*. 2006;2006:
397 1–5. doi:10.1155/IDOG/2006/23125
- 398 30. Mahande AM, Mahande MJ. Prevalence of parasitic infections and associations with pregnancy
399 complications and outcomes in northern Tanzania: A registry-based cross-sectional study. *BMC*
400 *Infect Dis*. *BMC Infectious Diseases*; 2016;16: 1–9. doi:10.1186/s12879-016-1413-6
- 401 31. Rahman MM, Abe SK, Rahman MS, Kanda M, Narita S, Bilano V, et al. Maternal anemia and
402 risk of adverse birth and health outcomes in low- and middle-income countries: systematic review
403 and meta-analysis. *Am J Clin Nutr*. American Society for Nutrition; 2016;103: 495–504.
404 doi:10.3945/ajcn.115.107896
- 405 32. McSorley HJ, Maizels RM. Helminth infections and host immune regulation. *Clin Microbiol Rev*.
406 2012;25: 585–608. doi:10.1128/CMR.05040-11
- 407 33. Borkow G, Bentwich Z. Chronic parasite infections cause immune changes that could affect
408 successful vaccination. *Trends Parasitol*. 2008;24: 243–245. doi:10.1016/j.pt.2008.02.009

- 409 34. Wammes LJ, Hamid F, Wiria AE, May L, Kaisar MMM, Prasetyani-Gieseler MA, et al.
410 Community deworming alleviates geohelminth-induced immune hyporesponsiveness. *Proc Natl*
411 *Acad Sci U S A*. 2016;113: 12526–12531. doi:10.1073/pnas.1604570113
412 35. Clark DA. The importance of being a regulatory T cell in pregnancy. *J Reprod Immunol*. Elsevier
413 Ireland Ltd; 2016;116: 60–69. doi:10.1016/j.jri.2016.04.288
414 36. Seavey MM, Mosmann TR. Immunoregulation of fetal and anti-paternal immune responses.
415 *Immunol Res*. 2008;40: 97–113. doi:10.1007/s12026-007-8005-x
416 37. Mpairwe H, Tweyongyere R, Elliott A. Pregnancy and helminth infections. *Parasite Immunol*.
417 2014;36: 328–337. doi:10.1111/pim.12101
418 38. Blackwell AD. Helminth infection during pregnancy: Insights from evolutionary ecology. *Int J*
419 *Womens Health*. 2016;8: 651–661. doi:10.2147/IJWH.S103529
420